Control of Cyclin B1 localization through regulated binding of the nuclear export factor CRM1

Jing Yang,1 Elaine S.G. Bardes,1 Jonathan D. Moore,1 Jennifer Brennan,1 Maureen A. Powers,2 and Sally Kornbluth1,3

1Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710 USA; 2Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia 30322 USA

Activation of the Cyclin B/Cdc2 kinase complex triggers entry into mitosis in all eukaryotic cells. Cyclin B1 localization changes dramatically during the cell cycle, precipitously transiting from the cytoplasm to the nucleus at the beginning of mitosis. Presumably, this relocalization promotes the phosphorylation of nuclear targets critical for chromatin condensation and nuclear envelope breakdown. We show here that the previously characterized cytoplasmic retention sequence of Cyclin B1, responsible for its interphase cytoplasmic localization, is actually an autonomous nuclear export sequence, capable of directing nuclear export of a heterologous protein, and able to bind specifically to the recently identified export mediator, CRM1. We propose that the observed cytoplasmic localization of Cyclin B1 during interphase reflects the equilibrium between ongoing nuclear import and rapid CRM1-mediated export. In support of this hypothesis, we found that treatment of cells with leptomycin B, which disrupted Cyclin B1–CRM1 interactions, led to a marked nuclear accumulation of Cyclin B1. In mitosis, Cyclin B1 undergoes phosphorylation at several sites, a subset of which have been proposed to play a role in Cyclin B1 accumulation in the nucleus. Both CRM1 binding and the ability to direct nuclear export were affected by mutation of these phosphorylation sites; thus, we propose that Cyclin B1 phosphorylation at the G2/M transition prevents its interaction with CRM1, thereby reducing nuclear export and facilitating nuclear accumulation.

[Key Words: CRM1; CRS phosphorylation; cell cycle; Cyclin B1; cellular localization; nuclear export]

Received December 2, 1997; revised version accepted May 18, 1998.
regulators appear to be restricted in subcellular localization has important implications for the regulation of entry into mitosis, because particular regulators of Cdc2 may only have access to a subset of Cdc2/cyclin complexes. Furthermore, distinct Cdc2/cyclin complexes may be responsible for different aspects of mitosis because their accessibility to key substrates will depend on their localization. Coordination between the nuclear events of mitosis (e.g., nuclear envelope breakdown, chromosome condensation) and the cytoplasmic events of mitosis (e.g., Golgi disassembly, spindle formation) requires appropriately timed activation of Cdc2/Cyclin B kinases in both subcellular compartments. Thus, the mechanisms underlying the subcellular distribution of these key regulators are of great interest for understanding the regulated and concerted nature of the G2/M transition.

Recent work by a number of groups has revealed that nuclear trafficking of proteins is mediated by a family of saturable receptors that cooperate with soluble factors and nuclear pore proteins to move transport cargo in and out of the nucleus (for review, see Gorlich andMattaj 1996; Corbett et al. 1997; Doye et al. 1997; Ullman et al. 1997). Recently, several such receptors have been discovered, including the importin α/β heterodimer, which mediates binding to classical nuclear localization sequences (NLSs) (Gorlich et al. 1994, 1995; Radu et al. 1995), transportin, which binds to a nuclear shuttling sequence (M9 confers bidirectional transport) (Pollard et al. 1996), and CRM1, a receptor for leucine-rich nuclear export sequences (NESs) (Fornerod et al. 1997; Fukuda et al. 1995), transportin, which mediates binding to classical nuclear localization sequences (NLSs) (Gorlich et al. 1994, 1995; Radu et al. 1995), transportin, which binds to a nuclear shuttling sequence (M9 confers bidirectional transport) (Pollard et al. 1996), and CRM1, a receptor for leucine-rich nuclear export sequences (NESs) (Fornerod et al. 1997; Fukuda et al. 1995; Neville et al. 1997; Ossareh-Nazari et al. 1997; Stade et al. 1997).

Analysis of chimeras between human Cyclin A (which is constitutively nuclear) and human Cyclin B1 in HeLa cells led to the discovery of a domain of Cyclin B1 (amino acids 109–151), which was necessary for the interphase localization of Cyclin B1 and sufficient to target Cyclin A to the cytoplasm (Pines et al. 1994). This domain was called the cytoplasmic retention sequence (CRS), based on the hypothesis that it acts as an anchoring site to tether Cyclin B1 to cytoplasmic components. In this report we show that rather than promoting cytoplasmic retention, the Cyclin B1 CRS is actually an NES that can autonomously direct export of a heterologous protein and confers binding to the nuclear export receptor, CRM1. Our results imply that the predominantly cytoplasmic accumulation of Cyclin B1 in interphase results from continuous nuclear import and rapid re-export rather than cytoplasmic immobilization.

In Xenopus, the CRS region of Cyclin B1, which is 61% identical to that of human Cyclin B1, contains four conserved serine phosphorylation sites. Mutation of these sites to alanine abolished the ability of the cyclin to promote oocyte maturation (Li et al. 1995, 1997). Biological activity was restored to this mutant when a nuclear localization sequence was fused to the amino terminus of the protein, suggesting that CRS phosphorylation might be important for nuclear accumulation of Cyclin B1 during oocyte maturation. We demonstrate here that binding of the CRS to CRM1 is inhibited by phosphorylation within the CRS, suggesting that cyclin phosphorylation can reduce its rate of nuclear export, promoting nuclear accumulation and entry into mitosis.

Results

Because Cyclin B1 phosphorylation site mutants have been phenotypically characterized in Xenopus oocytes and oocytes provide an experimentally tractable system in which to study nuclear transport, we wished to examine the regulation of Cyclin B1 localization in this system. Xenopus oocytes, which are physiologically arrested in G2, were manually separated into nuclear and cytoplasmic fractions. We found that Cyclin B1 was predominantly cytoplasmic (Fig. 1A), with a small fraction of the Cyclin B1 in the nucleus (germinal vesicle, GV). In theory, this cytoplasmic accumulation of Cyclin B1 could be the result of a lack of nuclear import (as would occur if the CRS bound to a cytoplasmic anchor) or to a steady state in which nuclear export of Cyclin B1 was more rapid than its import. To determine whether Cyclin B1 could serve as a nuclear export substrate, full-length Cyclin B1 was translated in vitro in reticulocyte lysates in the presence of [35S]methionine and injected into nuclei of stage VI oocytes. Immediately after injection or 4 hr after injection, the oocytes were dissected manually into nuclear and cytoplasmic fractions. Suc-
cessfully injected oocytes were identified by the presence of pink nuclei, reflecting the presence of hemoglobin from the reticulocyte lysate. The nuclear and cytoplasmic fractions were analyzed by SDS-PAGE and autoradiography for the presence of radiolabeled protein. Only 12% of injected cyclin remained in the nuclei after 4 hr showing that Cyclin B1 can be actively exported (Fig. 1B).

In the several cases examined thus far, nuclear protein export requires the GTPase Ran/TC4. A Ran T24N mutant, locked in its GDP-bound form, blocks export of nuclear proteins, as does nuclear injection of RanGAP protein, which accelerates hydrolysis of GTP by Ran (Gorlich et al. 1997: Richards et al. 1997). To determine whether cyclin nuclear export was affected by Ran–GDP, we coinjected oocyte nuclei with 35S-labeled Cyclin B1 and purified T24N Ran protein or recombinant RanGap protein. Both of these treatments led to a significant diminution in the export of Cyclin B1 from the nucleus into the cytoplasm (Fig 2; data not shown). This suggests that the GTP-bound form of Ran is likely to be required for nuclear export of Cyclin B1, as has been shown for other actively exported proteins (Gorlich et al. 1997; Richards et al. 1997).

Given the ability of Cyclin B1 to be exported from nuclei, we suspected that the CRS might actually mediate nuclear export of the cyclin, rather than blocking its nuclear import. To determine whether the CRS could promote nuclear export of a heterologous protein, we linked the isolated CRS from Xenopus Cyclin B1 (amino acids 76–125) to the carboxyl terminus of glutathione S-transferase (GST). GST–CRS or GST protein alone was then injected into nuclei (with dextran blue to identify oocytes with injected nuclei), and nuclear and cytosolic fractions were dissected at various times after injection and examined for the distribution of injected protein by immunoblotting with anti-GST sera. Although GST protein is small (25 kD), it is known to dimerize, and >90% of the injected GST protein was retained in the nucleus over a 7 hr time course (data not shown). Thus, GST protein is effectively too large to exit the nucleus by passive diffusion through pores, as has been noted by others (Wen et al. 1995; Moyer et al. 1996). In contrast, the injected GST–CRS protein was exported rapidly from the nuclei (Fig 3). These data demonstrate that the CRS can act as an autonomous NES.

Because the CRS could mediate nuclear export of Cyclin B1, we wished to determine whether the recently identified NES from protein kinase inhibitor (PKI) (Wen et al. 1995) could compete with Cyclin B1 for the nuclear export machinery. Human serum albumin was conjugated to multiple copies of the NES from PKI, or to an inactive scrambled mutant variant of the PKI NES (called PKI NOS) to serve as a control. These conjugates were then coinjected along with 35S-labeled Cyclin B1 into oocyte nuclei, and the location of the cyclin was examined 3 hr and 5 hr after injection as described above. Nuclear export of Cyclin B1 was delayed by the PKI–NES, but not by the NOS mutant (Fig 4A,B). Addition-
the CRS also might promote binding to CRM1. To determine if this was the case, we coupled the GST–CRS fusion protein to a glutathione–Sepharose resin and used it as a bait to retrieve CRS-binding proteins from extracts of Xenopus oocytes. After incubation in Xenopus oocyte extracts, the beads were pelleted gently by centrifugation, washed extensively, and the bead-bound material was processed for immunoblotting with anti-CRM1 antisera. As shown in Figure 5A, the GST–CRS protein was able to bind to CRM1. No specific interaction between the CRS and other CRM1-related proteins implicated in protein export, including RanBP7 (Gorlich et al. 1997) and CAS (Scherf et al. 1996; Kutay et al. 1997) was detected in parallel experiments. (Fig. 5B). In addition, no bound CRM1 was detected with GST protein alone (Fig. 5A). Similarly, we found that recombinant GST–CRM1 protein linked to Sepharose beads could bind specifically to full-length, in vitro-translated Cyclin B1 (Fig. 5E). Thus, the nuclear export of Cyclin B1 may be mediated by CRM1.

Recently, it has been reported that the drug leptomycin B can specifically bind CRM1, thereby inhibiting CRM1-dependent nuclear protein export. Consistent with a role for CRM1 in export of Cyclin B1, we found that export of radiolabeled Cyclin B1 was effectively inhibited by treatment of oocytes with 200 nM leptomycin B (Fig. 5C,D). Moreover, leptomycin B treatment of egg extracts also prevented binding of CRM1 to the B1 CRS (Fig 5A).

Mutational analysis of a CRM1-dependent export substrate, HTLV I Rex protein, has identified a loose consensus NES (see Fig. 6A; Bogerd et al. 1996). By scanning the Cyclin B1 sequence, we noted a sequence conforming to the NES consensus within the CRS (amino acids 76–125). We therefore tested whether this sequence also acts as a nuclear export signal.

Figure 3. The CRS mediates nuclear export of Cyclin B1. (A) The isolated CRS from Xenopus Cyclin B1 (amino acids 76–125) was linked to the carboxyl terminus of GST. Either GST or GST–CRS protein was injected into oocyte nuclei along with 14C-labeled BSA. Oocytes were dissected at 0, 30, and 50 min after injection. Proteins were analyzed by SDS-PAGE followed by immunoblotting with GST antibody and detection with 125I-labeled protein A (quantitated by PhosphorImager). 14C-Labeled BSA was detected by autoradiography. (B) The graph represents a quantitation of the data in A, showing the percentage of injected proteins remaining in nuclei at 0 and 50 min.

Figure 4. The PKI NES reduces nuclear export and induces nuclear accumulation of Cyclin B1. (A) Human serum albumin was conjugated with the NES peptide from PKI (HSA–NES), or to an inactive scrambled mutant variant of the PKI NES as the unexportable control (HSA–NOS). The 35S-labeled Cyclin B1 and 14C-labeled BSA mixture was injected into oocyte nuclei either with 8 µg/µl HSA–NES or HSA–NOS. Oocytes were dissected at 0, 3, and 5 hr after injection, and proteins were analyzed by SDS-PAGE followed by autoradiography. (B) The data in A are graphed to show the change in ratio of nuclear/cytoplasmic injected Cyclin B1 over a 5-hr time course. (C) HSA–NES or HSA–NOS (16 µg/µl) was injected into oocyte nuclei with 10 µg/µl dextran blue 2000 as an injection marker. Oocytes were dissected at 0, 7, and 12 hr after injection and proteins were analyzed by SDS-PAGE followed by immunoblotting with Cyclin B1 antibody. (D) The amount of cyclin present in the nucleus at time 0 was quantitated; the increase in nuclear cyclin after PKI NES injection is plotted as a percentage of cyclin quantities initially found in the nucleus.
108–117) of Xenopus Cyclin B1 (Fig. 6A). We mutated one of the critical hydrophobic residues (F112) to an alanine to determine whether this would affect the NES function of the CRS. As shown in Figures 6, C and D, 35S-labeled F112A mutant Cyclin B1 injected into oocyte nuclei was not exported. In addition, an F112A mutant CRS variant no longer bound to CRM1 (Fig. 6E). Although this mutation disrupted the ability of Cyclin B1 to export from nuclei, it did not perturb its ability to interact with its binding partner, Cdc2 (Fig. 6B).

If cytoplasmic retention of Cyclin B1 is a consequence of CRM1-mediated export, then leptomycin B might be expected to induce nuclear accumulation of endogenous Cyclin B1. Treatment of oocytes with 200 nM leptomycin B induced gradual accumulation of nuclear Cyclin B1, consistent with the hypothesis that Cyclin B1 can shuttle through nuclei (Fig. 7A,B). We did not observe a concomitant decrease in the cytoplasmic level of Cyclin B1 because the cytoplasmic pool of Cyclin B1 in Xenopus oocytes is quite large and the cytoplasmic/nuclear ratio is >6:1. Injection of 35S-labeled Cyclin B1 into the cytoplasm of leptomycin B-treated oocytes or cytoplasmic injection of the F112A mutant protein also led to a slow nuclear accumulation of cyclin (data not shown). However, the nuclear accumulation of RanBP1, a shuttling component of the nuclear trafficking machinery, was considerably more striking, demonstrating that the nuclear transport machinery of the oocyte was fully operative (Fig. 7A,C). Therefore, we considered the possibility that slow nuclear import of Cyclin B1 might be a feature of the meiotically arrested G2 oocyte; progression to meiotic GV breakdown (at the G2/M transition) can take longer than 12 hr after treatment of oocytes with the meiotic inducer progesterone. To keep Cyclin B1 in the oocyte cytoplasm would require only that the rate of export exceeds the rather slow import rate.

Given these data, we sought to examine the effects of leptomycin B treatment on nuclear Cyclin B1 accumulation in actively cycling somatic cells. Untreated HeLa cells or HeLa cells treated with 20 nM leptomycin B for varying times were lysed and separated into nuclear and cytoplasmic fractions by centrifugation at 1000 g for 10 min. The pelleting of nuclei was confirmed by staining of the pellet with the fluorescent DNA intercalating dye Hoechst 33258. Nuclei were washed twice in PBS, and the nuclear and cytoplasmic fractions were resolved by SDS-PAGE. Immunoblotting of these fractions with a monoclonal antibody directed against human Cyclin B1 revealed that significant amounts of Cyclin B1 had accumulated in HeLa nuclei within 4 hr of leptomycin B treatment (Fig. 8A,B; compare this with the 38 hr time course in Xenopus oocytes). In addition, in HeLa cells, cytoplasmic depletion of Cyclin B1 was seen concomitant with nuclear accumulation. These results were confirmed by processing leptomycin B-treated HeLa cells for indirect immunofluorescence with the anti-Cyclin B1

14C-labeled BSA mixture was then injected into oocyte nuclei. Oocytes were dissected at 0, 3, and 7 hr after injection and proteins were analyzed by SDS-PAGE followed by autoradiography. (D) The graph represents a quantitation of the data in C, showing the percentage of injected proteins remaining in nuclei at 0 and 7 hr. (E) Human Crm1 was fused to the carboxyl terminus of GST protein. Either GST alone or GST–Crm1 fusion protein was coupled to glutathione-Sepharose beads. Twenty microliters of each resin was incubated with 2 µl of 35S-labeled Cyclin B1 in 100 µl of buffer with 0.3 µg/µl Ran G19V (a mutant form of Ran that lacks GTPase activity and hence remains constitutively GTP-bound) and 5 µM GTP at room temperature for 1 hr. The beads were then pelleted and washed three times with oocyte extract buffer. The beads-bound proteins were analyzed by SDS-PAGE followed by autoradiography.
monoclonal antibody. In untreated HeLa cells, Cyclin B1 is excluded from nuclei during interphase (Fig. 8C, top panel), as reported previously. The sharp boundary caused by the concentration of cyclin in perinuclear regions creates the appearance of a nuclear rim; however, this does not represent binding of Cyclin B1 to the nuclear envelope. In untreated cells, the occasional prophase cell could be seen staining with this antisera, consistent with the reported rapid entry of Cyclin B1 into nuclei just prior to entry into mitosis (data not shown; Pines and Hunter 1991). However, when HeLa cells were treated for 4 hr with leptomycin B, there was a dramatic nuclear accumulation of Cyclin B1 in a large proportion of interphase cells; a representative photomicrograph of such cells is shown in Figure 8C (bottom panel). To facilitate comparison, treated and untreated cells were photographed under the same conditions; this results in a somewhat overexposed nuclear signal in the leptomycin-treated cells in which cyclin is strongly concentrated in the nucleus. These results are entirely consistent with the idea that Cyclin B1 can cycle through the nucleus during interphase. In support of this hypothesis, Pines and colleagues, using time-lapse video microscopy, have observed cycling of GFP-labeled Cyclin B1 through nuclei during interphase; this cycling is abolished by leptomycin B treatment (J. Pines, pers. comm.).

As mentioned above, phosphorylation of four sites (serines 94, 96, 101, and 113) within the CRS is thought to affect Cyclin B1 localization (Li et al. 1997). Given our findings, it seemed possible that phosphorylation might modulate the ability of the CRS to bind to CRM1 and thereby regulate its nuclear export rate. To test this model, we produced isolated GST–CRS fusion proteins in which the four serines in the CRS had been mutated to either Ala (nonphosphorylatable) or Glu (which often mimics constitutive phosphorylation). Beads coupled to each of these fusion proteins were incubated in oocyte extract and then examined for binding to CRM1 by immunoblotting with anti-CRM1 antibody.

Figure 6. Cyclin B1 contains a Rev/Rex consensus NES within the CRS region. (A) The NESs of vertebrate Cyclin B1s were aligned and compared with the consensus sequence for a functional Rev/Rex NES. (B) A full-length Cyclin B1 mutant in which the Phe residue at position 112 was changed to Ala was translated in vitro and added to interphase extracts of Xenopus eggs (these contain Cdc2, but lack mitotic cyclins). The 35S-labeled F112A mutant cyclin and wild-type cyclin were similarly retrieved from extracts by p13 Sepharose (which can only bind Cyclin B1 indirectly through interactions with its binding partner, Cdc2), but not by control Sepharose. (C) A full-length Cyclin B1 mutant in which the conserved Phe-112 within CRS was mutated to Ala was translated in reticulocyte lysates in the presence of [35S]methionine and mixed with 14C-labeled BSA, a nonexportable injection control. The mixture was injected into Xenopus oocytes. After injection (0, 3, and 7 hr), the oocytes were dissected into cytoplasmic and nuclear fractions, proteins were extracted, and samples were then analyzed by SDS-PAGE, followed by PhosphorImager quantitation. (D) The graph represents a quantitation of the data in C, showing the percentage of injected proteins remaining in nuclei at the 0 and 7 hr time points. (E) Phe-112 of Cyclin B1 was mutated to Ala and the isolated CRS containing this mutation was fused to the carboxyl terminus of GST protein. GST alone, the wild-type GST–CRS protein, or F112A mutant GST–CRS protein were coupled to glutathione-Sepharose beads. Twenty microliters of each resin was incubated in oocyte extract for 60 min and the beads were then pelleted and washed three times with oocyte extract buffer. The bead-bound material was analyzed by SDS-PAGE followed by immunoblotting with anti-CRM1 antibody.
mutations was then translated in vitro and injected into oocyte nuclei to monitor the effect of the mutations on cyclin export. The Ala mutant was exported very efficiently, with only 11% remaining in the nucleus after 4 hours.

Figure 7. Leptomycin B treatment induces endogenous Cyclin B1 nuclear accumulation in Xenopus oocytes. (A) Oocytes were treated with 200 nM leptomycin B in MB buffer. At the indicated times after treatment, they were dissected into cytoplasmic and nuclear fractions. Proteins were extracted and analyzed by SDS-PAGE followed by immunoblotting with anti-Xenopus Cyclin B1 antibody. Although this antisera cross-reacts with other proteins from the extract, the indicated band is Cyclin B1; this has been confirmed by specific reactivity of the antisera against recombinant Cyclin B1 and not B2, and by observation of the periodic accumulation and destruction of this band in cycling extracts of Xenopus eggs. The samples blotted with anti-cyclin sera were also immunoblotted with anti-Ranbp1 sera, as a positive control protein for nuclear accumulation following leptomycin B treatment. (B) The graph represents a quantitation of the data in A, showing the fold increase of endogenous Cyclin B1 accumulated in nuclei at the indicated times after leptomycin B treatment. For every oocyte nuclear equivalent loaded on the gels, only one-eighth the amount of cytoplasm was loaded to facilitate observation of potential changes in cytoplasmic levels of protein. (C) The graph represents a quantitation of the data in A, showing the fold increase of endogenous RanBP1 in nuclei following leptomycin B treatment.

Figure 8. Leptomycin B treatment induces nuclear accumulation of Cyclin B1 in HeLa cells. (A) HeLa cells were treated with 20 nM leptomycin B. At the indicated times, cells were collected and separated into cytoplasmic and nuclear fractions. Samples were analyzed by SDS-PAGE followed by Western blot with anti-human Cyclin B1 antibody (Santa Cruz). All of the nuclear or cytoplasmic fraction from 1.5 x 10^6 HeLa cells were loaded in each lane, as indicated. (B) The graph represents a quantitation of the data in A, showing the fold increase of endogenous Cyclin B1 in HeLa cell nuclei following leptomycin B treatment. Note the much shorter time course shown here than in the Xenopus experiment in 7B (4 hr vs. 40 hr). (C) Either untreated HeLa cells or HeLa cells treated for 4 hr with 20 nM leptomycin B were processed for indirect immunofluorescence with a monoclonal directed against human Cyclin B1, as described in Materials and Methods. (Left) Cyclin B1 immunofluorescence signals in representative interphase cells either treated or untreated with leptomycin B. (Right) The same cells stained with the DNA intercalating dye, Hoechst 33258. Fluorescence was observed and photographed with a 60x Planochromat objective and CCD camera.
We have demonstrated that the CRS sequence of Cyclin B1 can serve as a nuclear export sequence that targets Cyclin B1. The CRS contains an NES recognized by CRM1, which binds to the carboxy terminus of GST–CRS proteins. The GST–CRS proteins were coupled to glutathione–Sepharose beads and incubated in oocyte extracts. The bound material was analyzed by SDS-PAGE followed by immunoblotting with anti-CRM1 antibody. We observed that CRM1 from oocyte extracts bound preferentially to the GST–CRS wild-type protein compared with the GST–CRS Ala mutant (Fig. 9A). One possible explanation for this discrepancy between CRM1-binding and nuclear export rates would be that the degree of phosphorylation of the wild-type GST–CRS was different from the CRM1-binding experiment and in this export experiment. In the CRM1-binding assay the GST–CRS was incubated in total oocyte extract, whereas in the export assay, the GST–CRS was injected directly into nuclei. As expected, in total oocyte extracts we found a robust kinase activity able to phosphorylate the wild-type CRS (Fig. 10F). However, when the GST–CRS fusion protein was incubated in equal amounts of total protein from separate nuclear and cytoplasmic extracts (equivalent to nuclei from 45 oocytes and cytoplasm from 3.6 oocytes), seven times more phosphate was incorporated into the CRS in the cytoplasmic extract than in the presence of GV extract (Fig. 10F). The low level of CRS phosphorylation observed in nuclear extracts suggested that the large bolus of GST–CRS protein that we injected into nuclei (Fig. 10B) may have overwhelmed the basal nuclear kinase activity, thereby minimizing differences between the (largely unphosphorylated) wild-type CRS protein and (unphosphorylatable) Ala proteins. To test this hypothesis we varied the amount of GST–CRS Ala and GST–CRS wild-type proteins injected; reducing the level of injected protein accentuated the difference in export rates of the Ala and wild-type GST–CRS proteins. One such experiment is shown in Figure 10D, in which 2.5-fold less protein was injected than in the experiments shown in Figure 10B. Under these circumstances, the GST–CRS wild-type protein was exported more slowly than the GST–CRS Ala mutant (Fig. 10D,E). Collectively, these data lead us to postulate that CRS phosphorylation occurs at high levels in the cytoplasm and at low levels in the nucleus during interphase.

**Discussion**

The CRS contains an NES

interphase, it remained formally possible that the Ala and Glu mutants grossly altered the efficiency of nuclear import of the exported Cyclin B1, rather than simply affecting export. To circumvent this problem, we analyzed the trafficking of the GST–CRS fusion proteins, because GST, which lacks a nuclear localization sequence, is not reimported into nuclei (Fig. 10A). Injection of the wild-type and mutant Glu GST–CRS fusion proteins into oocyte nuclei revealed that the GST–CRS Glu mutant was exported more slowly than the wild-type GST–CRS (Fig. 10B).

In this experiment, the GST–CRS Ala mutant was exported from nuclei at a rate comparable with the wild-type GST–CRS (Fig. 10B,C), with 7% of the wild-type and 3% of the Ala mutant protein remaining in the nucleus after 70 min (as compared with 25% of the Glu mutant). This was somewhat surprising, because we had observed that CRM1 from oocyte extracts bound preferentially to the GST–CRS Ala mutant compared with the wild-type GST–CRS (Fig. 9A). One possible explanation for this discrepancy between CRM1-binding and nuclear export rates would be that the degree of phosphorylation of the wild-type GST–CRS was different from the CRM1-binding experiment and in this export experiment. In the CRM1-binding assay the GST–CRS was incubated in total oocyte extract, whereas in the export assay, the GST–CRS was injected directly into nuclei. As expected, in total oocyte extracts we found a robust kinase activity able to phosphorylate the wild-type CRS (Fig. 10F). However, when the GST–CRS fusion protein was incubated in equal amounts of total protein from separate nuclear and cytoplasmic extracts (equivalent to nuclei from 45 oocytes and cytoplasm from 3.6 oocytes), seven times more phosphate was incorporated into the CRS in the cytoplasmic extract than in the presence of GV extract (Fig. 10F). The low level of CRS phosphorylation observed in nuclear extracts suggested that the large bolus of GST–CRS protein that we injected into nuclei (Fig. 10B) may have overwhelmed the basal nuclear kinase activity, thereby minimizing differences between the (largely unphosphorylated) wild-type CRS protein and (unphosphorylatable) Ala proteins. To test this hypothesis we varied the amount of GST–CRS Ala and GST–CRS wild-type proteins injected; reducing the level of injected protein accentuated the difference in export rates of the Ala and wild-type GST–CRS proteins. One such experiment is shown in Figure 10D, in which 2.5-fold less protein was injected than in the experiments shown in Figure 10B. Under these circumstances, the GST–CRS wild-type protein was exported more slowly than the GST–CRS Ala mutant (Fig. 10D,E). Collectively, these data lead us to postulate that CRS phosphorylation occurs at high levels in the cytoplasm and at low levels in the nucleus during interphase.
Cyclin B1 for CRM1-mediated nuclear export during interphase. This suggests that the predominantly cytoplasmic localization of Cyclin B1 at this time is the result of a dynamic traffic in which cyclin transits continually in and out of the nucleus.

Recent studies have shown that the leucine-rich NES of PKI directs nuclear export through association with the export mediator CRM1 (Fornerod et al. 1997; Neville et al. 1997; Ossareh-Nazari et al. 1997; Stade et al. 1997). We have shown that the Cyclin B1 CRS also binds to CRM1, and that cyclin export is delayed by an excess of the PKI NES. We also found that cyclin export was slowed by depletion of Ran–GTP, which was proposed to be a cofactor for nuclear protein export (Richards et al. 1997). Although the sequence requirements for NES function are only loosely defined, the CRS does contain a sequence LCQAFSDVLI (residues 108–117 of Xenopus Cyclin B1) that resembles the sequences critical for functioning of the HIV Rev, HTLV I Rex, and PKI NESs, at least in the spacing of hydrophobic amino acids (Fischer et al. 1995; Wen et al. 1995; Bogerd et al. 1996). We found that altering a critical hydrophobic residue in that sequence (F112) abolished both CRM1 binding and nuclear export of Cyclin B1. Collectively, our data strongly suggest that the Cyclin B1 CRS directs export from the nucleus via a CRM1-mediated pathway similar to that recently characterized for PKI.

Regulation of Cyclin B1 export through CRS phosphorylation

Previous studies established that Cyclin B1 undergoes phosphorylation at four serine residues within the CRS (Izumi and Maller 1991; Li et al. 1995). Data from several studies suggests that phosphorylation is a general feature of B-type cyclins from many species (Meijer et al. 1989; Gautier and Maller 1991; Izumi and Maller 1991), although a function for these phosphorylations has not been established. The data presented here indicate that CRS phosphorylation can have a significant impact on Cyclin B1 localization by reducing the affinity of Cyclin B1 for CRM1, thereby decreasing its nuclear export rate. A nonphosphorylatable mutant of Cyclin B1 maintained high export rates, and prevented nuclear accumulation of Cyclin B1, potentially explaining the failure of this mutant to promote oocyte maturation. In contrast, a mutant

nuclear fractions and extracts were prepared from each fraction or from whole oocytes. Each extract was diluted to 1.45 μg/μl. Twenty microliters of GST–CRS wild-type beads was incubated in 45 μl of total (T), cytoplasmic (C), or nuclear (N) oocyte extract, 1 μM cold ATP and 15 μCi of [γ-32P]ATP. After 20 min incubation at room temperature, beads were pelleted and washed with extract buffer three times. The bead-bound material was analyzed by SDS-PAGE, developed by PhosphorImager and quantitated.
designed to mimic full phosphorylation of Cyclin B1 interacted much more weakly with CRM1 and was exported from the nucleus more slowly.

Whereas the cell cycle regulation of phosphorylation at sites within the CRS has not been examined specifically, Kobayashi et al. (1991) noted a Cyclin B1 modification (detected as a mobility shift of the protein in denaturing gels) in Xenopus oocytes that increased concomitant with germinal vesicle breakdown, perhaps indicating an increase in CRS phosphorylation. Given our findings, it is tempting to speculate that the rapid accumulation of Cyclin B1 in the nucleus at the G2/M transition could be governed by increasing phosphorylation of CRS residues, thereby reducing the affinity of Cyclin B1 for CRM1 and decreasing nuclear export.

In addition to the CRS phosphorylation-mediated control of nuclear export rates, it is possible that nuclear import rates are regulated and contribute to the relocalization of Cyclin B1 at the G2/M transition. Neither Cyclin B1 nor Cdc2 contains a classical NLS, and the mechanism by which the Cdc2/Cyclin B1 complex enters the nucleus is not yet clear. However, we have found that the nuclear import factor, importin β, can bind to Cdc2/Cyclin B1 complexes and experiments are in progress to determine whether this association reflects a role for importins in mediating nuclear import of CDK/Cyclin complexes (J.D. Moore and S. Kornbluth, unpubl.). Although the possibility that nuclear import can be regulated by changes in CRS phosphorylation clearly merits further investigation, it is interesting to note that Ala and Glu mutant Cyclin B1 proteins bind equally well to importin β (J.D. Moore and S. Kornbluth, unpubl.).

Localization of enzymes controlling Cyclin B1 CRS phosphorylation

The identity of the kinase(s) responsible for phosphorylating sites within the CRS remains unknown. On the basis of sequence comparisons with consensus substrate sites, Li et al. (1997) suggested that a MAP kinase or Cdc2/cyclin itself might phosphorylate Ser-94 or Ser-96 [as observed in vitro by Izumi and Maller (1991)], and that casein kinase II might phosphorylate Ser-101 and Ser-113 (Li et al. 1997). The latter site is adjacent to one of the conserved hydrophobic residues in the part of the CRS resembling the Rev and PKI NESs. It is unclear which of the phosphorylation sites regulate the CRS-CRM1 interaction, or whether multiple sites are involved. Further studies into the particular sites involved and the enzymes that control their phosphorylation are underway.

Even without detailed information regarding the identity of the CRS kinase(s) and phosphatase(s), our data suggest that a further layer of regulation may stem from differential localization of these enzymes. At high levels of injected protein, we found that the nuclear export rates of wild-type and nonphosphorylatable GST–CRS fusion proteins injected into the nucleus were very similar. Because phosphorylation of the wild-type CRS would have slowed its export, this result suggested that the CRS-directed kinase activities are relatively scarce in the interphase nucleus or that CRS phosphatases are very active in the nucleus, or both. Phosphorylation of the CRS was very low in nuclear extracts compared with that seen in cytoplasmic extracts, in which the CRS-CRM1 interaction was impaired relative to the nonphosphorylatable mutant.

When we injected lower levels of GST–CRS protein, the Ala and the wild-type proteins were exported at different rates, consistent with the results obtained with the full-length cyclins. These data suggested that nuclear kinases could phosphorylate the trace amounts of radio-labeled full-length cyclins injected, but that the higher amounts of injected GST–CRS protein exceeded the ability of the nuclear kinases to maintain a high stoichiometry of phosphorylation on the wild-type GST–CRS.

It is not clear why the GST–CRS fusion proteins are exported more rapidly than the full-length cyclin protein. The full-length cyclin has the capacity to be reimported into nucleus after export, whereas the GST–CRS fusion protein does not. However, the slow rate of nuclear accumulation of Cyclin B1 in leptomycin B-treated oocytes suggests that reimport may not have a significant effect on total nuclear efflux during a typical 8 hr nuclear export experiment. Therefore, we consider it possible that the context in which the CRS appears determines the nuclear export rate of the CRS-containing protein, or reimport of recently exported Cyclin B1 is more rapid than import of the overall pool, reflected by the slow accumulation of nonexportable cyclin. Although the full-length cyclins and the GST–CRS proteins were exported at different rates, the export rate of wild-type CRS-containing proteins consistently exceeded that of Glu CRS-containing proteins. This suggests that injected wild-type CRS-containing proteins were never fully phosphorylated in any of our experiments and that elevating phosphorylation of the CRS within the nucleus could provide an effective means of increasing nuclear accumulation of cyclin at the G2/M transition.

Functional implications of Cyclin B1 export

The accumulation of nuclear Cyclin B1 after leptomycin B treatment was less striking in Xenopus oocytes than in HeLa cells. Whether this represents a species difference or a difference in the import pathways operating in these two cell types bears further investigation. However, in both systems it appears that Cyclin B1 can be imported into nuclei during interphase, despite the fact that the steady state favors localization of Cyclin B1 to the cytoplasm.

It seems likely that the slow apparent import rate of Cyclin B1 we observed in the leptomycin B-treated oocytes reflects the nature of the G2-arrested oocyte system: Unprimed Xenopus oocytes can take >12 hr to accumulate sufficient active nuclear Cdc2/Cyclin B for germinal vesicle breakdown in response to progesterone treatment, presumably reflecting, at least in part, the slow accumulation of nuclear Cdc2/Cyclin B as oocytes
transition from G$_2$/M. The fact that the gradual accumulation of Cyclin B1 in oocytes, which we observed when nuclear export was blocked, may be physiologically significant is suggested by preliminary experiments in which mRNA encoding the F112A mutant Cyclin B1 produced more rapid progression through the mitotic G$_2$/M transition than did similarly injected wild-type Cyclin B1 mRNA (J. Yang and S. Kornbluth, unpubl.).

In the somatic cell cycle, nuclear shuttling during interphase provides an appealing mechanism for coordinating nuclear and cytoplasmic aspects of entry into mitosis. The fact that a single Cdc2/cyclin complex can receive inputs from both nuclear and cytoplasmic regulators provides a simple way of integrating different signals from these compartments. For instance, entry into mitosis is predicated on the completion of DNA replication and repair of DNA damage (Murray et al. 1992). In the absence of these conditions, cell cycle checkpoints act to inhibit Cdc2/cyclin activation. Transit of Cdc2/Cyclin B1 complexes through the nucleus provides the opportunity for these complexes to continuously sample the nuclear environment and receive checkpoint information without invoking nucleocytoplasmic trafficking of checkpoint signals.

In addition to receiving inputs from different compartments, the shuttling of Cdc2/Cyclin B1 complexes between nucleus and cytoplasm may help to ensure that nuclear envelope breakdown, chromosome condensation, spindle formation, and other events of mitosis are appropriately timed and that the nucleus and cytoplasm enter mitosis simultaneously.

Materials and methods

In vitro translation

Xenopus Cyclin B1 wild-type, Ala, and Glu mutants were kindly provided by Dr. D. Donoghue (University of California, San Diego) in the vector SP64T, containing cyclin variants cloned downstream of an SP6 promoter. Wild-type Xenopus Cyclin B1 cDNA in the pSP64T vector was used as the template. The primers were (1) 5'-GCTAGC-GATGTCCTCATTCAGTTAACGATTTGATG, in which a silent mutation was used to generate an NheI site to facilitate mutant selection; and (2) 3'-AGCCCGCAGGCTCAT-CAGGGAGGCAACC.

Expression and purification of recombinant proteins

The isolated CRS from Xenopus Cyclin B1 (amino acids 76-125), or mutant variants in which the four phosphorylated Ser residues had been mutated to Glu or Ala were cloned into the vector pGexKG to generate GST–CRS fusion proteins. All constructs and the vector alone were expressed in Topp 3. Escherichia coli (Stratagene). The recombinant fusion proteins were expressed and purified as described (Solomon et al. 1992).

Preparation of total, cytoplasm, and nuclear oocyte extracts

Xenopus oocytes were prepared and manually dissected as described above. Either total, cytoplasm or nuclear fractions were homogenized in extract buffer (20 mM HEPES, 0.25 M sucrose, 0.1 mM NaCl, 2.5 mM MgCl$_2$ at pH 7.2) and centrifuged twice at 13,000 g for 10 min. The clear supernatants were collected and diluted to 1.45 mg/ml for assays of GST–CRS phosphorylation.

Phosphorylation assay

Twenty microliters of glutathione-Sepharose beads coupled to GST or to GST–CRS wild-type, Ala, or Glu was incubated in 45 µl of extract with 1 µM ATP and 15 µCi [$_{32}$P]ATP at room temperature for 20 min. The beads were then pelleted and washed with 1 ml of extract buffer three times. The bead-bound material was analyzed by SDS-PAGE followed by autoradiography.

Pull-down experiments

GST fusion proteins were coupled to glutathione-Sepharose beads and blocked with boiled fetal bovine serum to block non-specific interactions of proteins with the sepharose beads. The beads were then incubated with either oocyte extract or in vitro-translated protein in boiled fetal bovine serum at 4°C for an hour. The beads were then washed with EB buffer and the binding proteins were resolved by SDS-PAGE followed by immunoblotting or autoradiography.

Fractionation of HeLa cell extracts

Two subconfluent 10-cm dishes of HeLa cells were treated with 20 nM leptomycin B. At various timepoints, cells were washed with PBS and scraped off the dish and harvested by centrifugation at 1 K for 10 min at 4°C. Cells were then resuspended in hypotonic buffer (20 mM Tris-HCl at pH 7.4, 10 mM KCl, 1 mM
EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin) for 10 min on ice and lysed by dounce homogenization. Nuclei were pelleted by centrifugation at 1 K for 10 min and washed with PBS twice. Both the cytoplasmic and nuclear fractions were mixed with SDS sample buffer and analyzed by SDS-PAGE and immunoblotting. The nuclear and cytoplasmic fractions were normalized to contain equal numbers of cell equivalents (∼1.5 × 10^7 cells/ lane).

Immunofluorescence

For immunolocalization of Cyclin B1, HeLa cells were grown to subconfluence on coverslips in DMEM with 10% fetal bovine serum. Where indicated, cells were incubated for 4 hr with the same medium containing 20 ng/ml leptomycin B. Leptomycin-treated or control coverslips were fixed at room temperature with 4% paraformaldehyde and then permeabilized with cold 2% Triton X-100 in PBS. Nonspecific sites were blocked by incubation with 2% BSA, 0.2% Triton X-100 in PBS, followed by incubation with a monoclonal antibody to human Cyclin B1 (GN51, 1/200; Santa Cruz Biotechnology). Bound antibody was detected with RITC-conjugated antibody to mouse IgG1. During the final wash, cells were stained with Hoechst 33258 to visualize the DNA, after which they were mounted on slides with gelvatol.

Acknowledgments

We are grateful to Dr. Jonathan Pines for sharing his results with us prior to publication, and for suggesting the F112A mutant. We thank Dr. Minoru Yoshida for generously providing leptomycin B. We thank Ashley Smith for her assistance with the immunofluorescence. Dr. Katherine Swenson made these experiments possible by providing helpful advice and a rapid and excellent tutorial in oocyte injection, for which we are grateful. We thank Dr. D. Forbes for her generous support and for providing for the synthesis of the PKI NES and NOS peptides and conjugates. We thank Dr. G. Grosfeld for generously providing anti-CRM1 antisera, Dr. J. Maller for anti-Cyclin B1 sera, Dr. M. Dasso for anti-RanBP1, and Drs. U. Brinkmann and D. Gorlich for kindly providing anti-CAS and anti-RanBP7 sera. We thank Dr. F. Melchior for her gift of purified RanGAP and Dr. D. Donoghue for the Ala and Glu mutant Cyclin B1 clones. We thank Dr. K. Ullman for protocols and advice. We thank Dr. D. Lew for critical reading and editing of the manuscript. This work was supported by a grant from the American Cancer Society to I.W. Mattaj, for the synthesis of the PKI NES and NOS peptides and conjugates.

The publication costs of this article were defrayed in part by page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact.

References

CRM1-mediated Cyclin B1 nuclear export


